Royalty Pharma: Unique, Diversified Life Science And Biopharma Pure Play

Royalty Pharma plc is the global leader in acquiring biopharmaceutical royalties, offering investors exposure to blockbuster therapies and megatrend-driven growth. RPRX focuses on de-risked, post-proof-of-concept assets, delivering attractive risk-adjusted returns with a return on invested capital around 15% and equity returns near 21%. The business model is defensive, uncorrelated with macro trends, and benefits from scale, high operating margins, and expert capital allocation.